WNT3: Potential Drug Target and Biomarker for Many Diseases (G7473)

Target Name: WNT3

NCBI ID: G7473

WNT3

WNT3: Potential Drug Target and Biomarker for Many Diseases

WNT3 (Wnt-3) is a protein that is expressed in many tissues throughout the body, including the brain, nervous system, and endodermal tissues. It is a key regulator of the Wnt signaling pathway, which is a critical pathway that regulates cell proliferation , differentiation, and survival. Mutations in the Wnt signaling pathway have been linked to a wide range of developmental and physiological processes, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified WNT3 as a potential drug target for a variety of therapeutic applications, including the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. WNT3 has also been shown to be involved in the development and progression of certain types of cancer, including breast cancer.

One of the key reasons for the potential utility of WNT3 as a drug target is its involvement in the regulation of cell proliferation and differentiation. In many tissues, WNT3 plays a role in the regulation of the number and type of cells that are produced, as well as the timing of cell division. This regulation is critical for the development and maintenance of tissues and organs, and is often disrupted in diseases such as cancer and neurodegenerative diseases.

In addition to its role in cell proliferation and differentiation, WNT3 is also involved in the regulation of cell adhesion and migration. These processes are critical for the formation and maintenance of tissues and organs, and are often disrupted in diseases such as cancer and neurodegenerative diseases.

Another potential mechanism by which WNT3 may be involved in the development and progression of certain types of cancer is its role in the regulation of angiogenesis, the formation of new blood vessels that can supply oxygen and nutrients to tumor cells. This regulation is critical for the growth and survival of tumors, and is often disrupted in cancer.

In addition to its potential clinical applications, WNT3 is also a potential biomarker for a variety of diseases. The Wnt signaling pathway has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the detection and measurement of WNT3 levels in tissues and fluids may be a useful diagnostic or predictive tool for these diseases.

Overall, WNT3 is a protein that has important roles in the regulation of cell proliferation and differentiation, as well as cell adhesion and migration, and in the regulation of angiogenesis. Its potential as a drug target and biomarker make it an attractive target for the development of new therapeutic approaches for a variety of diseases.

Protein Name: Wnt Family Member 3

Functions: Ligand for members of the frizzled family of seven transmembrane receptors (Probable). Functions in the canonical Wnt signaling pathway that results in activation of transcription factors of the TCF/LEF family (PubMed:26902720). Required for normal gastrulation, formation of the primitive streak, and for the formation of the mesoderm during early embryogenesis. Required for normal formation of the apical ectodermal ridge (By similarity). Required for normal embryonic development, and especially for limb development (PubMed:14872406)

The "WNT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WNT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets